LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...

LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024

Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...